DENTSPLY SIRONA (1XRAY) AI Stock Analysis
DENTSPLY SIRONA
(Milan:1XRAY)
No summary available
DENTSPLY SIRONA (1XRAY) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 1.97B
- Dividend Yield
- 5.94%
- Average Volume (3M)
- 592
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 0.98
- Revenue Growth
- -7.45%
- EPS Growth
- 46.36%
- Country
- Italy
- Employees
- 14,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
DENTSPLY SIRONA Business Overview & Revenue Model
Company Description
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Tech...
DENTSPLY SIRONA Earnings Call Summary
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company maintained its 2026 guidance for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50 (explicitly excluding the $44 million tariff refund and any incremental tariff impacts), while noting Q3 revenue should decline sequentially due to seasonality and Q3 earnings are expected below Q2 2026 levels excluding the $0.17 per‑share tariff refund benefit; Q2 results included $898 million of revenue (down 4.1% reported, down 6.3% constant currency, and down 3.6% CC after adjusting for Byte and a planned ~$8 million dealer inventory reduction), adjusted EPS of $0.52 (flat year‑over‑year), roughly flat adjusted EBITDA margins, operating cash flow of $99 million versus $48 million prior year, a $44 million tariff refund (≈$0.17/share) that enabled opportunistic repurchases of 1.3 million shares for ≈$12 million (average price below $10), ending cash of $239 million and net debt/EBITDA of 3.2x, and management said it expects the payoff from investments in sales, clinical education and R&D to become increasingly visible beginning in Q4.
DENTSPLY SIRONA Risk Analysis
DENTSPLY SIRONA disclosed 26 risk factors in its most recent earnings report. DENTSPLY SIRONA reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksDENTSPLY SIRONA Peers Comparison
Overall Rating
ISRG84Outperform
RMD81Outperform
BDX63.2Neutral
BAX52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ISRG | 84Outperform | $151.44B | 52.66 | 17.03% | ― | 20.45% | 8.75% |
| RMD | 81Outperform | $32.76B | 20.66 | 25.14% | 1.08% | 9.04% | 12.22% |
| BDX | 63Neutral | $54.10B | 59.69 | 3.79% | 2.01% | -2.56% | -40.38% |
| BAX | 52Neutral | $12.53B | -18.47 | -11.62% | 0.16% | 5.33% | -164.67% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:1XRAY | DENTSPLY SIRONA | 8.89 | -1.90 | -17.57% | |
| BAX | Baxter International Inc | 25.49 | 7.57 | 42.28% | |
| BDX | Becton, Dickinson and Co | 198.17 | 62.93 | 46.54% | |
| ISRG | Intuitive Surgical | 440.75 | -107.80 | -19.65% | |
| RMD | Resmed Inc | 227.08 | -15.57 | -6.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.